Topline data expected from Phase 2 LOTUS trial of abdakibart (AVTX-009) for the treatment of hidradenitis suppurativa in the second quarter of 2026 Cash, cash equivalents and short-term investments of approximately $98 million as of December 31, 2025 expected to provide runway into 2028WAYNE, Pa., March 23, 2026 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business updates and year-end financial results for 2025. “2025 was a year of disciplined execution focused on the LOTUS trial, and we are thrilled to be approaching a transformational milestone with our topline data release expected in the second quarter of 2026,” said Dr. Garry Neil, Chief Executive...

WeRide Inc. Announces Fourth Quarter and Full Year 2025 Unaudited Financial Results NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) — WeRide Inc. (“WeRide” or the “Company”) (Nasdaq: WRD; HKEX: 0800), a global leader in autonomous driving technology, today announced its unaudited financial results for the fourth quarter and full year 2025 ended December 31, 2025. Fourth Quarter 2025 Financial HighlightsTotal revenue was RMB314.0 million (US$44.9 million), representing an increase of 123.0% year over year.Product revenue was RMB211.4 million (US$30.2 million), representing an increase of 308.9% year over year, primarily attributable to increased revenue from robotaxi and robobus sales. Service revenue was RMB102.6 million (US$14.7 million), representing an increase of 15.2% year over year. Robotaxi revenue was RMB50.6 million (US$7.2...

ZUG, Switzerland, March 23, 2026 (GLOBE NEWSWIRE) — Lithium Argentina AG (“Lithium Argentina” or the “Company”) (TSX: LAR) (NYSE: LAR) today announced its fourth quarter and full year 2025 results. Unless otherwise stated, results are presented in United States dollars on a 100% basis. Sam Pigott, Lithium Argentina’s CEO, commented: “2025 was an exceptional year for Lithium Argentina. Cauchari-Olaroz ended the year near full capacity with costs coming in among the lowest reported for lithium chemical production globally. With the operation now generating significant cash flow, Cauchari-Olaroz distributed over $85 million ($42 million for our share), while closing a $130 million six-year debt facility further strengthening our balance sheet. “As we look at 2026, our priorities are clear. By building on Cauchari-Olaroz as a proven,...

MONTREAL, March 23, 2026 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis” or “the Company”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to heavy industry & defense, announces today that it will host a conference call at 12:00 PM Eastern Time on Tuesday, March 31, 2026 to discuss the Company’s financial results for the fourth quarter and fiscal year 2025, which ended December, 31, 2025, as well as provide an update to the Company’s progress and other developments. To access the conference call by telephone, please pre-register using the following link: https://register-conf.media-server.com/register/BI1585f76a7fae43d5b7d48d5ac1f689d5Registrants will receive confirmation with dial-in details. A live webcast of the conference...

Annual Report 2025Regulated information 21 March 2026 The board of directors of Financière de Tubize has established the 2025 annual report. This report is available on the website www.financiere-tubize.beProfit for the financial year: € 93.2 million (€ 90.1 million in 2024, + 3.5%), Full repayment of bank debt in May 2025 (€ 41.3 million at 31 December 2024), Acquisition, in 2025, of 24,487 UCB shares, at an average price of €178.27, for a total amount of €4.4 million, increasing the holding of the Company in UCB from 36.27% on 31 December 2024 to 36.28% on 31 December 2025.If the general shareholders meeting of 24 April 2026 approves the 2025 annual accounts, including the proposed result appropriation, a gross dividend of € 1.08 (compared to €1.04 for financial year 2024, an increase of 3.85%) will be payable as from 11 May 2026...

IRVINE, Calif., March 20, 2026 (GLOBE NEWSWIRE) — Cheetah Net Supply Chain Service Inc. (“Cheetah” or the “Company”) (Nasdaq CM: CTNT), a logistics and warehousing services provider, today reported results for the year ended December 31, 2025 and provided a corporate update. For the year ended December 31, 2025, the Company reported revenue of $1,288,536 from its logistics and warehousing business, compared to $455,805 in 2024, representing an increase of $832,731, or 182.7%. The Company recorded an operating loss of $4,579,576 for the year ended December 31, 2025, compared to an operating loss of $3,740,546 in 2024, representing an increase of $839,030, or 22.4%, primarily due to an impairment loss of $731,307 related to intangible assets and goodwill recorded during 2025. The Company recognized other income of $945,789 for the...

Evolution to Focus on Hospitality and Related Markets, Steady Product Revenue, Customer Growth and Expanding Leadership Team Exits FY25 with Strong Cash Position to Accelerate AI Platform and Products and New Corporate Initiatives AUSTIN, Texas, March 20, 2026 (GLOBE NEWSWIRE) — Phunware, Inc. (“Phunware” or the “Company”) (NASDAQ: PHUN), the enterprise cloud platform for mobile-first software products, solutions, data, and services to enable customers to engage, manage, and monetize their global audiences, today reported financial results for the fourth quarter and year ended December 31, 2025. Financial HighlightsNet revenue increased 33% to $0.8 million in Q4 2025, as compared to $0.6 million in Q4 2024. Gross margin improved to 57.7% in Q4 2025, as compared to 23.3% in Q4 2024, a 3,443 basis point improvement. Net loss improved...

FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVT Participants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic PSVT to sinus rhythm and did so more than 3x faster compared with placebo CARDAMYST launch execution on track with positive initial engagement in the product from healthcare providers and payers $200 million pro forma cash supports strong launch and operating runway into late 2027; includes $106 million of cash at year-end and net proceeds from subsequent financing activities1 Company to host investor call and webcast at 8:30am ET todayMONTREAL and CHARLOTTE, N.C., March 20, 2026 (GLOBE NEWSWIRE) — Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization...

SINGAPORE, March 20, 2026 (GLOBE NEWSWIRE) — BitFuFu Inc. (“BitFuFu” or the “Company”) (NASDAQ: FUFU), a world-leading Bitcoin miner and mining services innovator, today announced its unaudited financial results for the full year ended December 31, 2025. Full Year 2025 Financial HighlightsTotal revenue was $475.8 million in 2025, representing an increase of 2.7% from $463.3 million in 2024. The year-over-year increase was driven by higher revenue from Cloud Mining Solutions, Mining Equipment Sales, and Other, partially offset by a decline in revenue from Self-Mining Operations.    For the Year Ended December 31,      2025   2024Business Segment ($ in millions)   Revenue   % ofRevenue   Revenue   % ofRevenueCloud Mining Solutions   $      350.6     73.7 %     $       271.0     58.5 %  Self-Mining Operations     63.1     13.3 %       157.5     34.0 %  Mining...

KH Group Plc Stock Exchange Release 20 March 2026 at 8:45 am EET H Group Plc’s Financial Statements Release for 1 January – 31 December 2025 This is the summary of the Financial Statements Release for 2025. The full Financial Statements Release is attached to this release and is also available on the company’s website at www.khgroup.com A STRONG END TO 2025 KH Group, October–December 2025 Net sales amounted to EUR 63.3 (61.7) million. Comparable operating profit was EUR 4.2 (3.4) million. Operating profit was EUR 3.9 (3.1) million. Net profit for the period from continuing operations was EUR 2.1 (2.7) million Earnings per share (undiluted and diluted) from continuing operations were EUR 0.03 (0.04). KH Group, January–December 2025 Net sales amounted to EUR 204.5 (194.0) million. Comparable operating profit was EUR 6.4 (7.2) million. Operating...